By the time this press release is published, pegcetacoplan may have already been approved by the FDA (Food and Drug Administration) n the United States as the first treatment for geographic atrophy secondary to age-related macular degeneration. 2023 is showing to be a year of geographic atrophy with eighty-seven investigative treatments already in or about to be included in clinical trials, covering six different categories.

The categories include gene therapies for DR, DME, and AMD, geography atrophy, biosimilars, inherited retinal disorders, and devices. At the same time, some of the drugs are being introduced under new names, such as Tarcocimab terror, the new name for KSI-301, for example. There were significant approvals in 2022.

Two of the current trials of a novel 8mg, aflibercept formulation, known as high-dose aflibercept met their primary endpoints. The PHOTON trial in diabetic macular edema and the PULSAR trial in neovascular age-related macular degeneration, both demonstrated noninferiority in vision gains. This information is due to be submitted for review in the coming weeks.

AKST4290, an oral inhibitor blocking the action of eotaxin, an immunomodulatory protein that increases human age, and contributes to age-related disease is in phase Iib. This trial evaluated visual acuity outcomes after three loading doses in treatment-naive AMD patients.

Ray Man, the PA to Mahi Muqit, a Retinologist Specialist in the United Kingdom, said “Some of the more interesting introductions was Danicopan from Alexion Pharmaceuticals, an add-on therapy in a Phase II trial evaluating it as a monotherapy for geographical atrophy. The trial is due for completion in 2025. In addition to this, Elamipretide from Stealth biotherapeutics is going into Phase II studies as a cell-permeating peptide that failed to meet its primary endpoints. It has been well tolerated by participants.”

Mahi Muqit is watching the future unfold with great interest. As a passionate retinologist specialist in London, he takes great pride in providing his patients with first-class eye care and treatment with a passion for patients with diabetic retinopathy. He has volunteered extensively educating medical teams on this eye condition.

About Us: Mahi Muqit is a leading consultant ophthalmologist, cataract, and vitreoretinal surgeon at two private clinics in London, United Kingdom. He provides patients with superior service and support with a range of surgical procedures to meet their eyesight requirements. He has built up a solid reputation for his eye services in the London area as an expert eye doctor and surgeon offering surgical retina, medical retina, and complex cataract surgery. He also offers surgery to patients suffering from diabetic retinopathy. Mahi Muqit is a member of the Royal College of Ophthalmologists, a member of the British and Eire Association of Vitreoretinal Surgeons, and the UK and Ireland Society of Cataract and Refractive Surgeons. To find out more, visit https://www.retinasurgeon.uk.com/.